GATA-3 expression in the development of anterior chamber associated immune deviation.

Background: Anterior chamber associated immune deviation (ACAID) is characterized by a Th2 cell response. GATA-3 has been shown to be necessary for the activation of Th2 cells. This study was designed to examine the expression of GATA-3 in the development of ACAID.

[Clinical diagnosis and treatment of uveitis associated with ankylosing spondylitis].

Objective: To investigate the clinical features, diagnosis, treatment and prognosis of uveitis associated with ankylosing spondylitis (AS).

Methods: A history about low back pain was carefully reviewed in patients with uveitis and X-ray examination was performed if necessary. Forty-four patients were diagnosed as AS from January 1996 to June 2001 in Zhongshan Ophthalmic Center according to the modified New York criteria for AS.

[Quantitative determination of aqueous flare and cells in the eyes of patients with inflammation of anterior uvea].

Objective: To quantify aqueous flare and cells in the eyes of patients with inflammation of anterior uvea by FC-2000 laser flare cell meter (LFCM), and to compare these results with those obtained with slit lamp microscopy.

Methods: Aqueous flare and cells of 194 eyes of 110 patients with inflammation of anterior uvea and 52 eyes of 52 healthy subjects were graded into 0, 1+, 2+, 3+ and 4 + scale based on a previously described system using slit lamp microscopy. LFCM was also used for evaluation of aqueous flare and cells.

[Effect of endotoxin-induced uveitis on GATA-3 expression and ACAID development].

Objective: To investigate the changes of the GATA-3 expression and development of anterior chamber associated immune deviation (ACAID) after anterior chamber (AC) injection of interphotoreceptor retinoid binding protein (IRBP) under ocular inflammation.

Methods: ACAID was induced by injection of IRBP into the AC of 30 Spar-Dawley (SD) rats. Then the animals were divided into -4 days group, -24 hours group, 0 hour group, 3 days group, and 7 days group according to the lipopolysaccharide (LPS) injection 4 days and 24 hours before, or 0 hour, 3 days and 7 days after IRBP inoculation respectively.